Advanced search
Publication Cover
Current Eye Research Volume 12, 1993 - Issue 4
Submit an article Journal homepage
80
Views
39
CrossRef citations to date
0
Altmetric
Original Article

Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis

Jimmy D. Bartlett Department of Optometry, School of Optometry, University of Alabama at Birmingham, USA
,
John F. Howes Department of Optometry, School of Optometry, Pharmos Corporation, Alachua, FL, USA
,
N. Rex Ghormley Department of Optometry, School of Optometry, St Louis, MO, USA
,
John F. Amos Department of Optometry, School of Optometry, University of Alabama at Birmingham, USA
,
Robert Laibovitz Department of Optometry, School of Optometry, Austin, TX, USA
&
Barry Horwitz Department of Optometry, School of Optometry, Houston, TX, USA
Pages 313-321 | Received 13 Oct 1992, Accepted 01 Mar 1993, Published online: 02 Jul 2009

Citations (39)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (9)

Timothy L. Comstock & John D. Sheppard. (2018) Loteprednol etabonate for inflammatory conditions of the anterior segment of the eye: twenty years of clinical experience with a retrometabolically designed corticosteroid. Expert Opinion on Pharmacotherapy 19:4, pages 337-353.
Read now
Lian-Qun Wu, Xu Chen, Heng Lou, Jin-Wei Cheng & Rui-Li Wei. (2015) Loteprednol etabonate in the treatment of allergic conjunctivitis: a meta-analysis. Current Medical Research and Opinion 31:8, pages 1509-1518.
Read now
Minjie Chen, Lan Gong, Xinghuai Sun, Yangshun Gu, Xiangge He, Jia Qu, Lili Wang, Mingzhi Zhang & Xingwu Zhong. (2012) A multicenter, randomized, parallel-group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of Chinese patients with blepharokeratoconjunctivitis. Current Medical Research and Opinion 28:3, pages 385-394.
Read now
Jeremy B Wingard & Francis S Mah. (2011) Critical appraisal of bepotastine in the treatment of ocular itching associated with allergic conjunctivitis. Clinical Ophthalmology 5, pages 201-207.
Read now
Timothy L Comstock & Edward J Holland. (2010) Loteprednol and tobramycin in combination: a review of their impact on current treatment regimens. Expert Opinion on Pharmacotherapy 11:5, pages 843-852.
Read now
Eric M. White, Jonathan I. Macy, Kirk M. Bateman & Timothy L. Comstock. (2008) Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% withdexamethasone 0.1%/tobramycin0.3% in the treatment of blepharokeratoconjunctivitis. Current Medical Research and Opinion 24:1, pages 287-296.
Read now
Andrea Leonardi. (2005) Emerging drugs for ocular allergy. Expert Opinion on Emerging Drugs 10:3, pages 505-520.
Read now
Nicholas Bodor & Peter Buchwald. (2001) DRUG TARGETING BY RETROMETABOLIC DESIGN: SOFT DRUGS AND CHEMICAL DELIVERY SYSTEMS. Journal of Receptors and Signal Transduction 21:2-3, pages 287-310.
Read now
Melanie Hingorani. (1998) Drug therapy for ocular allergy. Expert Opinion on Investigational Drugs 7:1, pages 27-55.
Read now

Articles from other publishers (30)

Johannes Karl Fink. 2022. Contact Lenses. Contact Lenses 363 411 .
Fiona Stapleton, May Bakkar, Nicole Carnt, Robin Chalmers, Ajay Kumar Vijay, Sanjay Marasini, Alison Ng, Jacqueline Tan, Heidi Wagner, Craig Woods & James S. Wolffsohn. (2021) BCLA CLEAR - Contact lens complications. Contact Lens and Anterior Eye 44:2, pages 330-367.
Crossref
Sarah E. Kenny, Cooper B. Tye, Daniel A. Johnson & Ahmad Kheirkhah. (2020) Giant papillary conjunctivitis: A review. The Ocular Surface 18:3, pages 396-402.
Crossref
DeGaulle I. Chigbu, Pooja Jain & Zafar K. Khan. 2020. Advanced Concepts in Human Immunology: Prospects for Disease Control. Advanced Concepts in Human Immunology: Prospects for Disease Control 229 277 .
Megan E. CavetShellise GlogowskiEzra R. LoweEric Phillips. (2019) Rheological Properties, Dissolution Kinetics, and Ocular Pharmacokinetics of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%. Journal of Ocular Pharmacology and Therapeutics 35:5, pages 291-300.
Crossref
Abraham Solomon. (2016) Allergic manifestations of contact lens wearing. Current Opinion in Allergy & Clinical Immunology 16:5, pages 492-497.
Crossref
Paul Varner. (2015) Ophthalmic pharmaceutical clinical trials: design considerations. Clinical Investigation 5:5, pages 457-475.
Crossref
Neal P. Barney & Scott T. Bauer. 2014. Advances in Medical and Surgical Cornea. Advances in Medical and Surgical Cornea 27 43 .
Rajesh K. Rajpal, Raymond Fong & Timothy L. Comstock. (2013) Loteprednol Etabonate Ophthalmic Gel 0.5% Following Cataract Surgery: Integrated Analysis of Two Clinical Studies. Advances in Therapy 30:10, pages 907-923.
Crossref
Julie H. Tsai. 2013. Ocular Surface Disease: Cornea, Conjunctiva and Tear Film. Ocular Surface Disease: Cornea, Conjunctiva and Tear Film 111 115 .
Brett P. Bielory, Terrence P. O’Brien & Leonard Bielory. (2011) Management of seasonal allergic conjunctivitis: guide to therapy. Acta Ophthalmologica 90:5, pages 399-407.
Crossref
Timothy L. Comstock, Michael R. Paterno, Kirk M. Bateman, Heleen H. DeCory & Matthew Gearinger. (2012) Safety and Tolerability of Loteprednol Etabonate 0.5% and Tobramycin 0.3% Ophthalmic Suspension in Pediatric Subjects. Pediatric Drugs 14:2, pages 119-130.
Crossref
Timothy L. Comstock & Heleen H. DeCory. (2012) Advances in Corticosteroid Therapy for Ocular Inflammation: Loteprednol Etabonate. International Journal of Inflammation 2012, pages 1-11.
Crossref
Brett P Bielory, Victor L Perez & Leonard Bielory. (2010) Treatment of seasonal allergic conjunctivitis with ophthalmic corticosteroids: in search of the perfect ocular corticosteroids in the treatment of allergic conjunctivitis. Current Opinion in Allergy & Clinical Immunology 10:5, pages 469-477.
Crossref
Neal P. Barney, Frank M. Graziano, Ellen B. Cook & James L. Stahl. 2009. Middleton's Allergy: Principles and Practice. Middleton's Allergy: Principles and Practice 1117 1137 .
M. Omar F. Khan & Henry J. Lee. (2008) Synthesis and Pharmacology of Anti-Inflammatory Steroidal Antedrugs. Chemical Reviews 108:12, pages 5131-5145.
Crossref
William H Elhers & Peter C Donshik. (2008) Giant papillary conjunctivitis. Current Opinion in Allergy & Clinical Immunology 8:5, pages 445-449.
Crossref
Leonard Bielory. (2008) Ocular Allergy Treatment. Immunology and Allergy Clinics of North America 28:1, pages 189-224.
Crossref
Peter C. Donshik, William H. Ehlers & Mark Ballow. (2008) Giant Papillary Conjunctivitis. Immunology and Allergy Clinics of North America 28:1, pages 83-103.
Crossref
Edward J Holland, Jimmy D Bartlett, Michael R Paterno, Dale W Usner & Timothy L Comstock. (2008) Effects of Loteprednol/Tobramycin Versus Dexamethasone/Tobramycin on Intraocular Pressure in Healthy Volunteers. Cornea 27:1, pages 50-55.
Crossref
JOHN M. YANNI & NEAL P. BARNEY. 2008. Ocular Therapeutics. Ocular Therapeutics 239 274 .
Mark B. Abelson, Lisa Smith & Matthew Chapin. (2003) Ocular Allergic Disease: Mechanisms, Disease Sub-types, Treatment. The Ocular Surface 1:3, pages 127-149.
Crossref
Nicholas Bodor & Peter Buchwald. 2001. Drug Targeting Technology. Drug Targeting Technology.
Nicholas Bodor & Peter Buchwald. (2000) Soft drug design: General principles and recent applications. Medicinal Research Reviews 20:1, pages 58-101.
Crossref
N Bodor. (1999) Recent advances in retrometabolic design approaches. Journal of Controlled Release 62:1-2, pages 209-222.
Crossref
Siret D Jaanus, Ph.D. (1999) Ocular inflammatory disease: pharmacologic update. Clinical Eye and Vision Care 11:1, pages 3-12.
Crossref
STEVEN J. DELL, DAVID G. SHULMAN, GEORGE M. LOWRY & JOHN HOWES. (1997) A Controlled Evaluation of the Efficacy and Safety of Loteprednol Etabonate in the Prophylactic Treatment of Seasonal Allergic Conjunctivitis. American Journal of Ophthalmology 123:6, pages 791-797.
Crossref
MITCHELL H. FRIEDLAENDER & JOHN HOWES. (1997) A Double-masked, Placebo-controlled Evaluation of the Efficacy and Safety of Loteprednol Etabonate in the Treatment of Giant Papillary Conjunctivitis. American Journal of Ophthalmology 123:4, pages 455-464.
Crossref
Peter C. Donshik, FACS & William H. Ehlers. (1997) GIANT PAPILLARY CONJUNCTIVITIS. Immunology and Allergy Clinics of North America 17:1, pages 53-73.
Crossref
Peter C. Donshik & William H. Ehlers. (1997) GIANT PAPILLARY CONJUNCTIVITIS. Radiologic Clinics of North America 17:1, pages 53-73.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.